Abstract
Introduction/ObjectivesNintedanib is a tyrosine kinase inhibitor demonstrated to slow the rate of progression of fibrotic interstitial lung diseases (ILD). Originally available solely for the treatment of idiopathic pulmonary fibrosis (IPF),...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
